Nile Therapeutics Inc., of San Francisco, appointed Richard B. Brewer executive chairman...Hueneme, Calif., appointed Malcolm Gefter to its board and scientific advisory board

Lewis, who most recently served as president and CEO of the Juvenile Diabetes Research Foundation, has been serving as Ambit's executive chairman since March

Anaphore Inc., of La Jolla, Calif., named Russell G. Greig executive chairman...Cyntellect Inc., of San Diego, appointed Saiid Zarrabian president and CEO...and Jonathan M. Spergel to its scientific advisory board

Daryl Faulkner, who served as interim CEO, will continue as executive chairman of the company...IGEN Networks Corp., of Las Vegas, appointed Monty Ormsby president and Michael Grudman chief financial officer and secretary

King Pharmaceuticals Inc., of Bristol, Tenn., appointed Kevin S. Crutchfield and Derace Lan Schaffer to its board...Novavax Inc., of Rockville, Md., elected Stanley Erck executive chairman

team, with Greg Hamilton as chief operating officer and chief financial officer...Suzanne McDonald head of managed markets and government affairs...operations and also appointed Jon Terrett vice president of oncology at its San Jose, Calif

It also named Joseph S. Zakrzewski executive chairman, effective Jan. 1, 2010...Anesiva Inc., of South San Francisco, named Ted W. Love and David C. U'Prichard to its board, following completion of the merger with Arcion Therapeutics

Apthera Inc., of Scottsdale, Ariz., appointed Ira Z. Leiderman executive chairman and named Mary Ann Gray to the board...Dendreon Corp., of Seattle, elected Ian Clark and Pedro Granadillo to its board

ThalesNano, of Budapest, Hungary, named Dominic Gallello co-executive chairman...Third Rock Ventures LLC, of Boston, appointed Philip R. Reilly and Gregory L. Verdine venture partners, and Craig M. Greaves recruiting partner

Micromet Inc., of Bethesda, Md., named Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel...Myers, Fla., named Douglas M. VanOort to the board as executive chairman and interim CEO

Phase Bioscience Inc., of Morrisville, N.C., named Craig Rosen executive chairman...Potential Pharmaceuticals, of Louisville, Ky., appointed Johanna M. Seddon and Janet Stoltz Sunness to its scientific advisory board

Rib-X Pharmaceuticals Inc., of New Haven, Conn., appointed George M. Milne executive chairman...TheraGenetics Ltd., of Cambridge, Mass., and London, appointed Susan E. Bromley global head of R&D and named Kenneth B. Milne UK director of R&D

Biomedical Corp., of San Diego, appointed Punit S. Dhillon vice president of finance and operations...Biophan Technologies Inc., of Pittsford, N.Y., appointed Harold Gubnitsky, John Lanzafame and Travis E. Baugh to its board of directors...BioSeek Inc., of Burlingame, Calif., said that Roy A. Whitfield has been elected executive chairman of its board of directors

Draxis Health Inc., of Montreal, named Dan Brazier president and chief executive officer...Inc., of Bothell, Wash., appointed Bruce R. York secretary and interim chief financial officer...Pharmos Corp., of Iselin, N.J., named Robert F. Johnston executive chairman of its board of directors

Rainer Rogasch vice president of technical operations and development...Peptimmune Inc., of Cambridge, Mass., appointed Fredric Price executive chairman

ProtoKinetix Inc., of Vancouver, British Columbia, appointed Ross L. Senior president and CEO...Zila Inc., of Phoenix, named David R. Bethune executive chairman of its board of directors

Nucryst Pharmaceuticals Corp., of Wakefield, Mass., appointed Barry Heck executive chairman...Spaltudaq Corp., of Seattle, hired Matthew Moyle as senior vice president, chief development officer and Russ Hawkinson as vice president, finance and administration

Curidium Medica plc, of London, appointed Gosse Bruinsma an executive director and executive chairman, subject to shareholder approval...Diamics Inc., of Novato, Calif., named Mitchell Golbus chief medical and technical officer

His predecessor, Norman Pressman, was appointed executive chairman, while retaining his position as the chief scientific officer...Stephan Herrera senior director, investor relations and corporate affairs